AI Healthcare Operations
AI prior authorization software is moving from nice-to-have automation into regulated infrastructure. CMS finalized electronic prior authorization requirements in 2024 for many non-drug items and services, proposed a 2026 drug-focused interoperability rule on April 10, 2026, and is running the WISeR model from January 1, 2026 through December 31, 2031. The best platform for your team depends on whether you are reducing provider burden, modernizing utilization management, preparing for FHIR APIs, or improving denial and appeal analytics.
Healthcare operations adjacency
Credentialing, provider enrollment, roster quality, and payer readiness often sit upstream of coding, authorization, claims, and payer operations. Compare provider enrollment automation when provider data readiness is part of the workflow.
Do not choose a prior authorization platform only because the vendor says "AI." The useful question is where the software sits in the workflow. Provider-side teams need eligibility checks, requirement discovery, document extraction, submission, status tracking, denial reason capture, appeal support, and patient-access visibility. Payer and utilization-management teams need policy digitization, clinical criteria, reviewer queues, audit trails, analytics, metrics reporting, human clinical oversight, and integration with portals, EHRs, clearinghouses, pharmacy networks, and FHIR APIs.
The 2026 context also matters. CMS describes the 2024 Interoperability and Prior Authorization final rule as requiring impacted payers to implement and maintain a Prior Authorization API for non-drug items and services. On April 10, 2026, CMS proposed extending many aligned requirements to drug prior authorizations, including FHIR-related standards, API endpoint reporting, usage metrics, decision timeframes, and denial reason transparency. Buyers should treat AI as a workflow layer on top of those compliance, integration, and audit requirements.
| Tool | Best fit | Workflow strength | Buyer caveat |
|---|---|---|---|
| Cohere Health | Health plans and provider networks that need clinical intelligence across utilization management and authorization collaboration. | AI-assisted clinical workflows, EHR integration, interoperability positioning, human oversight, and payer/provider collaboration. | Validate exact product scope, implementation model, integrations, and BAA/security terms for your plan or provider environment. |
| Humata Health | Provider, pharmacy, and payer teams pursuing frictionless prior authorization across medical services, drugs, and review workflows. | Policy matching, submission support, automated statusing, analytics, audit trails, clinical bundling, and AI-driven clinical review. | Confirm which modules apply to your use case, payer mix, and WISeR-related workflow before treating it as a universal fit. |
| Myndshft | Revenue cycle and patient access teams that want prior authorization automation connected with eligibility and benefits workflows. | Automated PA intake, payer requirement discovery, document workflows, and RCM-oriented process automation. | Evaluate EHR, clearinghouse, payer, and specialty-drug coverage for your specific authorization volume. |
| CoverMyMeds | Medication access, pharmacy, and prescriber teams with heavy drug prior authorization needs. | Pharmacy prior authorization connectivity and medication access workflows. | It may not replace a full medical-service utilization management platform for procedures and non-drug services. |
| Availity | Provider organizations that already depend on payer portal connectivity and want authorization workflow support inside that network. | Payer connectivity, provider access, authorization workflows, and portal-oriented status visibility. | Confirm which AI capabilities are included versus partner-led or workflow automation capabilities. |
| Optum InterQual / Optum prior authorization tools | Payer and clinical-review teams that need criteria, guideline, and utilization management infrastructure. | Clinical criteria, review support, and recently announced digital prior authorization tooling. | Implementation and commercial fit will depend heavily on payer stack, contracts, and Optum product packaging. |
| Waystar | Provider revenue-cycle teams that want authorization work connected with broader claim and payment operations. | RCM workflow fit, payer connectivity, and operational visibility across patient financial workflows. | Validate AI-specific capabilities separately from general automation and clearinghouse connectivity. |
| PrescriberPoint | Prescriber and specialty medication teams exploring newer agentic AI prior authorization workflows. | Drug authorization assistance and prescriber workflow focus. | Its April 2026 announcement is timely, but buyers should request current production references, coverage, BAA terms, and workflow proof. |
| HealthEdge GuidingCare ecosystem | Health plans modernizing utilization management with partner AI ecosystems. | Decision intelligence across payer UM workflows, including partner capabilities from Anterior, Latitude Health, and Case Health AI. | Best evaluated as an ecosystem and integration decision, not as a single lightweight PA app. |
Cohere Health is the strongest shortlist entry when prior authorization is part of a broader clinical intelligence and payer/provider collaboration strategy. Its Cohere Unify platform messaging emphasizes AI-driven automation, EHR integration, clinical assistance, interoperability, safeguards for human oversight, and support for workflows across utilization management and payment integrity. Cohere also explicitly positions its platform around CMS-0057-F, CRD, DTR, and PAS API alignment.
Choose Cohere when the buyer is a health plan, delegated risk organization, specialty management group, or provider network that needs more than form-filling. It is a better fit when clinical policy digitization, reviewer support, provider collaboration, auditability, and API strategy all matter. Ask about the exact implementation path, Epic and portal integrations, payer-specific coverage, HITRUST/HIPAA controls, BAA terms, and how human review is enforced for clinical judgment.
Humata Health is a strong fit for teams that want prior authorization automation across providers, pharmacies, and payers. Its public site describes support for medical services, procedures, drugs, payer workflows, policy matching, policy intelligence, submission support, smart attestation answering, automated statusing, post-authorization monitoring, analytics, audit trails, AI-driven clinical review, and audit workflows.
Humata is especially relevant in 2026 because its site includes WISeR provider resources and CMS lists Humata Health among companies participating in the WISeR model. That does not make it the right choice for every organization, but it makes Humata a credible comparison point for teams watching Medicare review models, provider burden, and AI-assisted clinical review. Ask which payer, provider, pharmacy, EHR, and WISeR-specific workflows are in scope for your contract.
Myndshft is best considered by provider revenue-cycle, patient-access, and back-office teams that need prior authorization automation tied to eligibility, benefits, documentation, and payer requirements. It fits organizations trying to remove fax, portal, and manual follow-up work from high-volume authorization queues.
Before choosing Myndshft, map your authorization volume by service line, payer, specialty drug mix, EHR, clearinghouse, and denial pattern. The deciding factor is not whether the software can automate a generic PA task; it is whether it can discover the right requirements, prepare the right evidence, submit through the right channel, track status, and preserve enough audit detail to support denial analysis and appeals.
CoverMyMeds belongs on the shortlist when medication access is the center of the prior authorization problem. Pharmacy-benefit workflows are different from medical-service authorization workflows, and the 2026 CMS proposal explicitly separates medical-benefit drugs, pharmacy-benefit drugs, and standards such as NCPDP SCRIPT, Formulary & Benefit, and Real-Time Prescription Benefit.
Choose CoverMyMeds for pharmacy and prescriber connectivity rather than as a universal medical authorization platform. Buyers should confirm formulary, benefit, EHR, pharmacy, specialty medication, and payer coverage, plus how denial reasons, appeal workflows, and patient communications are handled.
Availity is relevant when payer connectivity and provider portal workflows are the operating center. Many provider organizations already depend on payer-network access, eligibility checks, claim status, and authorization-related workflows, so consolidating authorization status and submission work inside an existing network can be more practical than adding a new standalone tool.
Evaluate Availity by the payers and transaction types you actually use. Ask which authorization workflows are electronic versus portal-assisted, which fields are structured, which statuses come back automatically, and whether AI is native, partner-led, or limited to workflow assistance.
Optum is a better fit for organizations thinking about clinical criteria and utilization management infrastructure than for teams shopping only for a provider-side submission assistant. InterQual is a known clinical criteria asset, and Optum announced AI-powered digital prior authorization tools in 2026, according to healthcare trade coverage cited in the research return.
For payer and UM teams, the evaluation should focus on criteria governance, reviewer experience, EHR and payer-stack integration, explainability, appeals evidence, reporting, and oversight. For providers, the practical question is whether Optum tooling will reduce burden across the payers they submit to, not simply whether a payer-side tool exists.
Waystar is worth considering when prior authorization is one piece of a broader revenue-cycle automation program. Provider teams often need authorization status, eligibility, claim, denial, and payment workflows to connect cleanly rather than sit in separate queues.
The main caveat is AI specificity. Ask which prior authorization capabilities are AI-assisted, which are rules-based automation, which depend on payer connectivity, and how the platform stores denial reasons, supporting documents, and appeal history.
PrescriberPoint is a newer entrant to watch for prescriber-side drug authorization workflows. Its April 2026 announcement described an AI-powered prior authorization product for prescribers and reported clinician acceptance metrics. That makes it timely, but the right buyer posture is cautious validation rather than automatic adoption.
Request current customer references, supported drug classes, EHR workflow details, payer coverage, pharmacy benefit handling, HIPAA/BAA terms, data retention policies, human review controls, and evidence that the workflow reduces denials or rework in your specialty.
HealthEdge GuidingCare is relevant for payers that already use or are evaluating payer care management and utilization management infrastructure. Its February 2026 announcement described a Decision Intelligence ecosystem with Anterior, Latitude Health, and Case Health AI, which places it in the AI-enabled UM modernization conversation.
Evaluate this option as an enterprise ecosystem decision. Ask how partner AI outputs are governed, how clinical reviewers remain accountable, where audit trails live, how appeals data is captured, and how prior authorization metrics and API usage reporting can be supported.
Provider-side prior authorization tools should reduce intake work, avoid missing documentation, route requests to the right payer channel, track status, and feed denial and appeal analytics back into revenue-cycle operations. They should integrate with EHRs, practice management systems, clearinghouses, payer portals, pharmacy networks, and patient access workflows.
Payer-side and utilization-management tools should improve policy digitization, clinical review, criteria consistency, audit trails, provider communications, public metrics, and API readiness. They should not turn clinical judgment into an unsupported black box. CMS WISeR is explicit about using AI and machine learning along with human clinical review, which is the right risk lens for this category.
AI prior authorization software helps healthcare teams discover payer requirements, extract clinical documentation, prepare submissions, track status, support reviewer decisions, capture denial reasons, and analyze appeals. The best systems combine automation with structured integration, auditability, and human oversight.
No. CMS says the 2024 final rule did not require impacted payers to make real-time decisions through the Prior Authorization API. Automation can improve decision timeframes, but some cases still require clinical review.
The April 10, 2026 proposed rule would extend many aligned electronic prior authorization requirements to drugs, update FHIR and implementation-guide expectations, add endpoint and usage reporting, and increase transparency around decisions and denial reasons. Buyers should ask vendors how their roadmap handles these proposed requirements without assuming the proposal is final.
Neither is universally better. Provider-side tools reduce submission and follow-up burden. Payer-side tools improve utilization management, policy consistency, review operations, and reporting. Many enterprise workflows need both sides to interoperate.
Regulated buyers should be careful with autonomous claims. Use AI for requirement discovery, documentation support, prioritization, extraction, and decision support, while preserving human clinical review, audit trails, and appeal evidence for cases that require judgment.